Premium
Cardiac antibody–mediated rejection
Author(s) -
Chin Clifford
Publication year - 2012
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2012.01690.x
Subject(s) - medicine , plasmapheresis , immunoadsorption , antibody , rituximab , immunology , heart transplantation , panel reactive antibody , bortezomib , human leukocyte antigen , immune system , transplantation , antigen , multiple myeloma
Chin C. Cardiac antibody–mediated rejection. Abstract: Many factors limit short‐ and long‐term survival after pediatric heart transplantation. Historically, attention had been directed toward T‐cell responses and acute cellular rejection. Presence of pretransplant antibodies against HLA is associated with increased donor wait times and poor post‐transplant outcomes. Therapies aimed to mitigate circulating antibodies include plasmapheresis, protein A immunoadsorption columns, intravenous immune globulin, rituximab, and bortezomib. The negative effects of B cells, HLA antibodies, and AMR and potential interventions are the focus of this review article.